Caris Life Sciences Authorizes $100 Million Share Repurchase Program
核心洞察
Caris Life Sciences' Board of Directors has authorized a share repurchase program for up to $100 million of the company's outstanding common stock.
The repurchase program has no expiration date and may be executed through open market purchases, privately negotiated transactions, or Rule 10b5-1 trading plans.
The timing and amount of repurchases will depend on market conditions, stock price, financial performance, and other business factors at the company's discretion.
Caris Life Sciences (Nasdaq: CAI), a leading next-generation AI TechBio company and precision medicine pioneer, announced on June 8, 2026 that its Board of Directors has authorized a share repurchase program for up to $100 million of the company's outstanding common stock.
The Irving, Texas-based company may repurchase shares from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Open market repurchases will be structured to comply with applicable federal securities laws, including the pricing and volume requirements of Rule 10b-18.
Program Flexibility and Funding
The repurchase program does not obligate Caris to acquire any specific number of shares, has no expiration date, and may be modified, suspended, or discontinued at any time without prior notice at the discretion of the Board of Directors. The timing, manner, price, and amount of any repurchases will be determined at the company's discretion based on a variety of factors, including market conditions, the trading price of the company's common stock, financial condition and results of operations, capital requirements, general business conditions, alternative investment opportunities, and other factors deemed relevant. The company currently expects to fund the repurchase program from available cash and cash equivalents.
Caris Life Sciences: Precision Medicine and AI-Driven Diagnostics
Caris Life Sciences positions itself as a patient-centric, next-generation AI TechBio company actively developing and commercializing innovative solutions to transform healthcare. The company's platform is built on comprehensive molecular profiling — encompassing Whole Genome, Whole Exome, and Whole Transcriptome Sequencing — combined with advanced AI and machine learning capabilities. This convergence has enabled Caris to create a large-scale, multimodal clinico-genomic database and computing infrastructure designed to analyze and further unravel the molecular complexity of disease.
The company's technology platform supports the development of advanced precision medicine diagnostic solutions spanning early detection, diagnosis, monitoring, therapy selection, and drug development. Headquartered in Irving, Texas, Caris maintains offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland, with services provided in the U.S. and other international markets through the company or its distributor partners.
Forward-Looking Considerations
The announcement includes forward-looking statements subject to known and unknown risks and uncertainties. These include factors related to future financial performance, development and clinical validation of future solutions, commercial market acceptance, the competitive environment, third-party payer reimbursement, data management and AI integration capabilities, intellectual property protection, regulatory requirements — including the company's application for New York State Department of Health approval for Caris Assure — as well as data security, patient privacy, and cybersecurity considerations.